{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T10:30:21Z","timestamp":1778236221954,"version":"3.51.4"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ygyno.2025.10.013","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T01:08:48Z","timestamp":1761181728000},"page":"8-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Impact of neoadjuvant chemotherapy followed by interval debulking surgery on survival in women with advanced non-serous ovarian, fallopian tube, or primary peritoneal cancer"],"prefix":"10.1016","volume":"203","author":[{"given":"Hiroko","family":"Machida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Kawana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aikou","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Yamagami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Mandai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Kajiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikio","family":"Mikami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2025.10.013_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2025.10.013_bb0010","series-title":"Cancer Information Service","author":"Cancer Registry and Statistics","year":"2025"},{"key":"10.1016\/j.ygyno.2025.10.013_bb0015","series-title":"Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ\u00ae): Health Professional Version. PDQ Cancer Information Summaries","author":"Board PDQATE","year":"2002"},{"key":"10.1016\/j.ygyno.2025.10.013_bb0020","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2025.10.013_bb0030","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1200\/JCO-24-02589","article-title":"Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: ASCO guideline update","volume":"43","author":"Gaillard","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.10.013_bb0035","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2025.10.013_bb0040","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ygyno.2025.10.013_bb0045","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejca.2016.05.017","volume":"64","author":"Onda","year":"2016","journal-title":"Eur. J. Cancer (Oxford, England: 1990)"},{"key":"10.1016\/j.ygyno.2025.10.013_bb0050","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1136\/ijgc-2020-001640","article-title":"Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)","volume":"30","author":"Fagotti","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2025.10.013_bb0055","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ygyno.2019.03.243","article-title":"Trends and characteristics of epithelial ovarian cancer in Japan between 2002 and 2015: a JSGO-JSOG joint study","volume":"153","author":"Machida","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.10.013_bb0060","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1200\/JCO.2016.66.9010","article-title":"Randomized phase III trial of irinotecan plus cisplatin compared with paclitaxel plus carboplatin as first-line chemotherapy for ovarian clear cell carcinoma: JGOG3017\/GCIG trial","volume":"34","author":"Sugiyama","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.10.013_bb0065","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2019.30.e113","article-title":"Neoadjuvant chemotherapy for epithelial ovarian cancer in Japan: a JSGO-JSOG joint study","volume":"30","author":"Machida","year":"2019","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.10.013_bb0070","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1158\/1078-0432.CCR-10-3314","article-title":"IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer","volume":"17","author":"Anglesio","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2025.10.013_bb0075","article-title":"Annual report of the committee on gynecologic oncology, the Japan Society of Obstetrics and Gynecology: annual patient report for 2021 and annual treatment report for 2016","volume":"51","author":"Kajiyama","year":"2025","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"10.1016\/j.ygyno.2025.10.013_bb0080","author":"Japan Society of Obstetrics and Gynecology"},{"key":"10.1016\/j.ygyno.2025.10.013_bb0085","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"von Elm","year":"2007","journal-title":"BMJ (Clin. Res. Ed.)"},{"key":"10.1016\/j.ygyno.2025.10.013_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijgo.2013.10.001","article-title":"Staging classification for cancer of the ovary, fallopian tube, and peritoneum","volume":"124","author":"Prat","year":"2014","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"10.1016\/j.ygyno.2025.10.013_bb0095","author":"Ministry of health, labour and welfare"},{"key":"10.1016\/j.ygyno.2025.10.013_bb0100","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivar. Behav. Res."},{"key":"10.1016\/j.ygyno.2025.10.013_bb0105","first-page":"93","article-title":"The eighth edition AJCC Cancer staging manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2025.10.013_bb0110","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.ejso.2019.11.520","article-title":"Survival outcome and perioperative complication related to neoadjuvant chemotherapy with carboplatin and paclitaxel for advanced ovarian cancer: a systematic review and meta-analysis","volume":"46","author":"Machida","year":"2020","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2025.10.013_bb0115","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/ijgc-2019-000682","article-title":"TRUST: trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33\/AGO-OVAR OP7)","volume":"29","author":"Reuss","year":"2019","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2025.10.013_bb0120","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2020.31.e86","article-title":"Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept","volume":"31","author":"Jiang","year":"2020","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.10.013_bb0125","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1136\/ijgc-2024-005354","volume":"34","author":"Chiva","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2025.10.013_bb0130","article-title":"Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery","author":"Bryant","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ygyno.2025.10.013_bb0135","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1158\/1078-0432.CCR-20-0054","article-title":"CA-125 ELIMination rate constant K (KELIM) is a marker of chemosensitivity in patients with ovarian cancer: results from the phase II CHIVA trial","volume":"26","author":"You","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2025.10.013_bb0140","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1200\/JCO.2014.60.5212","article-title":"Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in Tubo-ovarian high-grade serous carcinoma","volume":"33","author":"B\u00f6hm","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.10.013_bb0145","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1136\/ijgc-2023-004872","article-title":"Clinical impact of CA-125 ELIMination rate constant K (KELIM) on surgical strategy in advanced serous ovarian cancer patients","volume":"34","author":"Bouvarel","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2025.10.013_bb0150","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.19.01009","article-title":"Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer","volume":"37","author":"Tewari","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.10.013_bb0155","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ygyno.2021.10.072","article-title":"Probability of detecting germline BRCA1\/2 pathogenic variants in histological subtypes of ovarian carcinoma. A meta-analysis","volume":"164","author":"Witjes","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.10.013_bb0160","doi-asserted-by":"crossref","first-page":"S570","DOI":"10.1016\/j.annonc.2024.08.812","volume":"35","author":"Aghajanian","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2025.10.013_bb0165","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1158\/1078-0432.CCR-24-3877","article-title":"Comparing Durvalumab, Olaparib, and Cediranib monotherapy, combination therapy, or chemotherapy in patients with platinum-resistant ovarian cancer with prior bevacizumab: the phase II NRG-GY023 trial","volume":"31","author":"Lee","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2025.10.013_bb0170","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1136\/ijgc-2023-004487","article-title":"Correlation between progression-free survival and overall survival in patients with ovarian cancer after cytoreductive surgery: a systematic literature review","volume":"33","author":"Chase","year":"2023","journal-title":"Int. J. Gynecol. Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825010376?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825010376?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T22:34:59Z","timestamp":1773095699000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825825010376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":33,"alternative-id":["S0090825825010376"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.10.013","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of neoadjuvant chemotherapy followed by interval debulking surgery on survival in women with advanced non-serous ovarian, fallopian tube, or primary peritoneal cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}